Some of these compounds are currently used in the clinic combined with 5-FU, such as irinotecan [49,50] or to treat other types of recurrent cancers, such as topotecan [51,52]; but we also found other compounds such as a norepinephrine inhibitor (amitriptyline), MEK inhibitors, a COX inhibitor, ivermectin, and the Rho-associated kinase inhibitor (Rockout), among others. Here, MAP2K7 is linked to cancer.